CETSA: a target engagement assay with potential to transform drug discovery

Future Medicinal ChemistryVol. 7, No. 8 EditorialCETSA: a target engagement assay with potential to transform drug discoveryAnnika Jenmalm Jensen, Daniel Martinez Molina & Thomas LundbäckAnnika Jenmalm JensenE-mail Address: annika.jenmalm-jensen@scilifelab.seDivision of Translational Medicine & Chemical Biology, Department of Medical Biochemistry & Biophysics, Karolinska Institutet, Tomtebodavägen 23A, 171 65 Solna, SwedenSearch for more papers by this author, Daniel Martinez MolinaPelago Bioscience AB, Nobels väg 3, 17165 Solna, SwedenSearch for more papers by this author & Thomas LundbäckDivision of Translational Medicine & Chemical Biology, Department of Medical Biochemistry & Biophysics, Karolinska Institutet, Tomtebodavägen 23A, 171 65 Solna, SwedenSearch for more papers by this authorPublished Online:11 Jun 2015https://doi.org/10.4155/fmc.15.50AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cellular thermal shift assayCETSAphenotypic-based drug-discoveryR&D efficiencytarget engagementtarget-based drug-discoveryReferences1 Arrowsmith J, Miller P. Trial watch: Phase II and Phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).Crossref, Medline, CAS, Google Scholar2 Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009).Crossref, Medline, CAS, Google Scholar3 Scannell J, Blanckley W, Boldon AH, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191–200 (2012).Crossref, Medline, CAS, Google Scholar4 Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).Crossref, Medline, CAS, Google Scholar5 Bunnage ME. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335–339 (2011).Crossref, Medline, CAS, Google Scholar6 Lee JA, Berg EL. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J. Biomol. Screen. 18, 1143–1155 (2013).Crossref, Medline, CAS, Google Scholar7 Morgan P, Van Der Graaf PH, Arrowsmith J et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012).Crossref, Medline, CAS, Google Scholar8 Cook D, Brown D, Alexander R et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).Crossref, Medline, CAS, Google Scholar9 Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov. Today 16, 1037–1043 (2011).Crossref, Medline, CAS, Google Scholar10 Bunnage ME, Chekler EL.P, Jones LH. Target validation using chemical probes. Nat. Chem. Biol. 9, 195–199 (2013).Crossref, Medline, CAS, Google Scholar11 Lanning BR, Whitby LR, Dix MM et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 1–10 (2014).Crossref, Google Scholar12 Swinney DC, Anthony J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011).Crossref, Medline, CAS, Google Scholar13 Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5, 821–834 (2006).Crossref, Medline, CAS, Google Scholar14 Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130–137 (2010).Crossref, Medline, CAS, Google Scholar15 Besnard J, Ruda GF, Setola V et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215–220 (2012).Crossref, Medline, CAS, Google Scholar16 Martinez Molina D, Jafari R, Ignatushchenko M et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).Crossref, Medline, Google Scholar17 Jafari R, Almqvist H, Axelsson H et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122 (2014).Crossref, Medline, CAS, Google Scholar18 Savitski MM, Reinhard FB, Franken H et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346 (6205), 1255784 (2014).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByCETSA and thermal proteome profiling strategies for target identification and drug discovery of natural productsPhytomedicine, Vol. 116Bruceine a exerts antitumor effect against colon cancer by accumulating ROS and suppressing PI3K/Akt pathway28 March 2023 | Frontiers in Pharmacology, Vol. 14Challenges and Perspectives in Target Identification and Mechanism Illustration for Chinese Medicine21 February 2023 | Chinese Journal of Integrative Medicine, Vol. 79Solasodine suppress MCF7 breast cancer stem-like cells via targeting Hedgehog/Gli1Phytomedicine, Vol. 107Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors13 May 2022 | Frontiers in Oncology, Vol. 12Photoaffinity Probe Reveals the Potential Target of Harringtonolide for Cancer Cell Migration Inhibition2 February 2022 | ACS Medicinal Chemistry Letters, Vol. 13, No. 3Site-Specific Labeling of Endogenous Proteins Using CoLDR Chemistry24 November 2021 | Journal of the American Chemical Society, Vol. 143, No. 48Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity3 December 2021 | Molecular Cancer Therapeutics, Vol. 20, No. 12Optimization of N -Phenylpropenoyl- l -amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease21 May 2021 | Journal of Medicinal Chemistry, Vol. 64, No. 11Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets29 April 2021 | Frontiers in Pharmacology, Vol. 12Validating Signal Transducer and Activator of Transcription (STAT) Protein–Inhibitor Interactions Using Biochemical and Cellular Thermal Shift Assays15 May 2020 | ACS Chemical Biology, Vol. 15, No. 7Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials20 February 2020 | ACS Infectious Diseases, Vol. 6, No. 4Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell deathScience Advances, Vol. 6, No. 12Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti‐Neuroinflammatory Agents for Ischemic Stroke27 December 2019 | Angewandte Chemie, Vol. 132, No. 6Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti‐Neuroinflammatory Agents for Ischemic StrokeAngewandte Chemie International Edition, Vol. 59, No. 6Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1European Journal of Pharmaceutical Sciences, Vol. 142Target 2035: probing the human proteomeDrug Discovery Today, Vol. 24, No. 11Affinity‐Based Chemoproteomics for Target Identification13 December 2019Bavachinin exhibits antitumor activity against non‑small cell lung cancer by targeting PPARγ11 July 2019 | Molecular Medicine ReportsCiRCus: A Framework to Enable Classification of Complex High-Throughput Experiments25 February 2019 | Journal of Proteome Research, Vol. 18, No. 4Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells17 January 2018 | Nature Communications, Vol. 9, No. 1Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1Bioorganic Chemistry, Vol. 79Cellular target engagement: a new paradigm in drug discoveryIvan Babic, Santosh Kesari & Elmar Nurmemmedov29 June 2018 | Future Medicinal Chemistry, Vol. 10, No. 14Identification and validation nucleolin as a target of curcumol in nasopharyngeal carcinoma cellsJournal of Proteomics, Vol. 182Size-Dependent Relationships between Protein Stability and Thermal Unfolding Temperature Have Important Implications for Analysis of Protein Energetics and High-Throughput Assays of Protein–Ligand Interactions14 August 2017 | The Journal of Physical Chemistry B, Vol. 122, No. 21Early Probe and Drug Discovery in Academia: A Minireview9 February 2018 | High-Throughput, Vol. 7, No. 1A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1SLAS Discovery, Vol. 23, No. 1Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers28 October 2017 | Cancers, Vol. 9, No. 12High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma4 December 2017 | Scientific Reports, Vol. 7, No. 1Mass Spectrometry in Biophysics: from High Throughput Screening to Structural BiologyGenotoxicity testing: progress and prospects for the next decade10 September 2017 | Expert Opinion on Drug Metabolism & Toxicology, Vol. 13, No. 10Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts7 February 2017 | Journal of Pharmacology and Experimental Therapeutics, Vol. 361, No. 1Applications of chemogenomic library screening in drug discovery20 January 2017 | Nature Reviews Drug Discovery, Vol. 16, No. 4The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers19 September 2016 | Scientific Reports, Vol. 6, No. 1Non-stoichiometric inhibition in integrated lead finding – a literature review31 December 2015 | Expert Opinion on Drug Discovery, Vol. 11, No. 2Advances in identification and validation of protein targets of natural products without chemical modification1 January 2016 | Natural Product Reports, Vol. 33, No. 5 Vol. 7, No. 8 STAY CONNECTED Metrics Downloaded 1,223 times History Published online 11 June 2015 Published in print June 2015 Information© Future Science LtdKeywordscellular thermal shift assayCETSAphenotypic-based drug-discoveryR&D efficiencytarget engagementtarget-based drug-discoveryFinancial & competing interests disclosureD Martinez Molina is a founder of Pelago Bioscience AB that commercializes the CETSA technology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download